Publications
Read the latest on Allena Pharmaceuticals.


Jan 2021
Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia
Pfau A. et al Nephrology Dialysis and Transplantation 2021
Dec 2020
Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria
D’Costa MR, et al. Nephrology Dialysis and Transplantation 2020
Oct 2020
Safety and Efficacy of Reloxaliase in Enteric Hyperoxaluria (EH): An Aggregate Review of Completed Studies.
Wyatt CM et al. Kidney Week 2020.
Oct 2020
Establishing Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria (URIROX-2).
Kausz AT et al. Kidney Week 2020.
Sep 2020
Pharmacodynamic (PD) Profiling of Reloxaliase in Patients with Severe Hyperoxaluria.
Knauf F et al. Kidney Week 2020
Nov 2019
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria (URIROX-2): A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study.
Kausz AT et al. Kidney Week 2019.
Nov 2019
A Phase 3, Randomized, Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria (URIROX-1): Clinical Characteristics and Burden of Illness.
Lieske JC et al. Kidney Week 2019.
Nov 2019
Pilot Study of Reloxaliase in Patients with Severe Enteric Hyperoxaluria and Hyperoxalemia: A Pro Tem Analysis of Study ALLN-177-206.
Knauf F et al. Kidney Week 2019.
Nov 2019
Dietary Oxalate Ingestion, Urinary Oxalate Levels, and Response to Reloxaliase in Three Phase II Studies.
Langman CB et al. Kidney Week 2019.
Nov 2019
Prevalence of Kidney Stones in Patients With Enteric Disorders.
Tasian GE et al. Kidney Week 2019.